A Study of LY4268989 (MORF-057) in Healthy Participants
A Phase 1 Study to Further Investigate the Pharmacokinetics, Safety and Tolerability, Food Effect and Drug-Drug Interaction of LY4268989 (MORF-057) in Healthy Participants
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
- Phone Number: 1-317-615-4559
- Email: LillyTrials@Lilly.com
Study Contact Backup
- Name: Physicians interested in becoming principal investigators please contact
- Email: clinical_inquiry_hub@lilly.com
Study Locations
-
-
California
-
Anaheim, California, United States, 92801
- CenExel ACT
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Are healthy as determined by medical evaluation including medical history, physical examination, laboratory test, electrocardiograms (ECGs), and vital signs.
- Cohort 5 includes Japanese participants. To qualify, the participants must be first-generation Japanese in the US, defined as the participant's biological parents, and all the participant's biological grandparents, being of exclusive Japanese descent, and being born in Japan.
- Cohort 5 includes Chinese participants. To qualify as Chinese for this study, all 4 of the participant's biological grandparents must be of exclusive Chinese descent and born in China.
- Have a body mass index within the range of 18.0 to 32.0 kilogram/square meter (kg/m²), inclusive, at screening.
Exclusion Criteria:
- Have a current or recent acute, active infection. For at least 30 days before screening and up to Day 1, participants must have no symptoms or signs of confirmed or suspected infection, and must have completed any appropriate anti-infective treatment.
- Have presence of significant uncontrolled respiratory, cerebrocardiovascular, cardiovascular, hepatic, renal, gastrointestinal, endocrine, hematologic, neurologic or psychiatric disorders, or abnormal laboratory values at screening that, in the opinion of the sponsor or investigator, pose an unacceptable risk to the participant if participating in the study or of interfering with the interpretation of data.
- Are immunocompromised to an extent that participation in the study would pose an unacceptable risk to the participant as determined by the investigator.
- Use or intend to use prescription or nonprescription medication, including dietary supplements, vitamins, herbal supplements, traditional Chinese medicine, or alternative medicines, within 14 days or 5 half-lives (whichever is longer), prior to dosing, unless, in the opinion of the investigator and sponsor, the medication will not interfere with the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: LY4268989 or Placebo Cohort 1 (Blinded)
Participants will receive LY4268989 orally or placebo single dose followed by BID administration
|
Administered orally
Administered placebo
|
|
Experimental: LY4268989 Cohort 2 (Open-Label)
Participants will receive LY4268989 orally tablet (formulation compared to capsule formulation) in a fasted state
|
Administered orally
|
|
Experimental: LY4268989 Cohort 3 (Open-Label)
Participants will receive multiple doses of LY4268989 orally BID administration with midazolam orally and intravenously (IV).
|
Administered orally
Administered orally
Administered intravenously (IV)
|
|
Experimental: LY4268989 or Placebo Cohort 4 (Blinded)
Participants will receive single escalating doses of LY4268989 orally or placebo
|
Administered orally
Administered placebo
|
|
Experimental: LY4268989 Cohort 5 (Blinded)
Participants will receive multiple doses of LY4268989 orally or placebo
|
Administered orally
Administered placebo
|
|
Experimental: LY4268989 Cohort 6 (Open-Label)
Participants will receive LY4268989 single dose orally in a fasted and fed state
|
Administered orally
|
|
Experimental: LY4268989 Cohort 7 (Open-Label)
Participants will receive multiple doses of LY4268989 orally BID administration in a fed state
|
Administered orally
|
|
Experimental: LY4268989 Cohort 8 (Open-Label)
Participants will receive multiple doses of LY4268989 orally BID administration with midazolam IV in a fasted state.
|
Administered orally
Administered orally
Administered intravenously (IV)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY4268989 (Cohort 1) and (Cohort 5)
Time Frame: Day 1 to Day 17
|
Day 1 to Day 17
|
|
|
PK: Area Under the Concentration Curve (AUC) of LY4268989 (Cohort 1) and (Cohort 5)
Time Frame: Day 1 to Day 17
|
Day 1 to Day 17
|
|
|
Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) (Cohort 1), (Cohort 3), and (Cohort 5)
Time Frame: Baseline to Study Completion (Up to Day 17)
|
A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the reported adverse events module
|
Baseline to Study Completion (Up to Day 17)
|
|
Number of Participants with TEAEs and SAEs (Cohort 4)
Time Frame: Baseline to Study Completion (Up to Period 4, Day 4)
|
A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the reported adverse events module
|
Baseline to Study Completion (Up to Period 4, Day 4)
|
|
PK: Cmax of LY4268989 (Cohort 2)
Time Frame: Day 1 to Day 13
|
Day 1 to Day 13
|
|
|
PK: AUC of LY4268989 (Cohort 2)
Time Frame: Day 1 to Day 13
|
Day 1 to Day 13
|
|
|
PK: Cmax of Midazolam and 1'-Hydroxymidazolam (Cohort 3)
Time Frame: Day 1 to Day 17
|
PK of midazolam and 1'-hydroxymidazolam (Cmax), when midazolam is administered alone and in the presence of LY4268989
|
Day 1 to Day 17
|
|
PK: Cmax of LY4268989 (Cohort 6)
Time Frame: Day 1 to Day 7
|
Day 1 to Day 7
|
|
|
PK: AUC of LY4268989 (Cohort 6)
Time Frame: Day 1 to Day 7
|
Day 1 to Day 7
|
|
|
PK: Cmax of LY4268989 (Cohort 7)
Time Frame: Day 1 to Day 12
|
Day 1 to Day 12
|
|
|
PK: AUC of LY4268989 (Cohort 7)
Time Frame: Day 1 to Day 12
|
Day 1 to Day 12
|
|
|
PK: AUC of Midazolam and 1'-Hydroxymidazolam (Cohort 3)
Time Frame: Day 1 to Day 17
|
PK of midazolam and 1'-hydroxymidazolam (AUC), where midazolam is administered alone and in the presence of LY4268989
|
Day 1 to Day 17
|
|
PK: AUC of Midazolam and 1'-Hydroxymidazolam (Cohort 8)
Time Frame: Day 3 and Day 11
|
PK of midazolam and 1'-hydroxymidazolam (AUC), where midazolam is administered alone and in the presence of LY4268989
|
Day 3 and Day 11
|
|
PK: Cmax of Midazolam and 1'-Hydroxymidazolam (Cohort 8)
Time Frame: Day 3 to Day 11
|
PK of midazolam and 1'-hydroxymidazolam (Cmax), when midazolam is administered alone and in the presence of LY4268989
|
Day 3 to Day 11
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
PK: Cmax of LY4268989 (Cohort 4)
Time Frame: Day 1 to Day 4
|
Day 1 to Day 4
|
|
PK: AUC of LY4268989 (Cohort 4)
Time Frame: Day 1 to Day 4
|
Day 1 to Day 4
|
|
PK: Cmax of LY4268989 (Cohort 3)
Time Frame: Time Frame: Day 6 to Day 15
|
Time Frame: Day 6 to Day 15
|
|
PK: AUC of LY4268989 (Cohort 3)
Time Frame: Time Frame: Day 6 to Day 15
|
Time Frame: Day 6 to Day 15
|
|
PK: Cmax of LY4268989 (Cohort 8)
Time Frame: Time Frame: Day 3 and Day 10
|
Time Frame: Day 3 and Day 10
|
|
PK: AUC of LY4268989 (Cohort 8)
Time Frame: Time Frame: Day 3 and Day 10
|
Time Frame: Day 3 and Day 10
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 27387
- J6E-MC-KWAC (Other Identifier: Eli Lilly and Company)
- MORF-057 (Other Identifier: Eli Lilly and Company)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.